Frier Levitt will host a May 15 webinar on legal risks, compounding regulations and market trends impacting GLP-1 prescribers ...

Eli Lilly (NYSE: LLY) was an unstoppable bet in the past few years, but LLY stock finally started plateauing in the latter ...

While M&A activity slowed in the first quarter of 2025, including in life sciences, there have been plenty of noteworthy developments in the ...

President Donald Trump's executive order mandates drugmakers to lower prices to match those in affluent nations, threatening ...

The executive order would require other countries to pay more for medications so that Americans could pay less. But experts ...

Eli Lilly is pumping iron in the GLP-1 prescription ring, gaining muscle with a 52.4% market share and a beefy $1,100 target.

President Donald Trump’s latest bid to slash prescription drug prices has once again stirred heated debate about the high ...

With the active ingredients in drugs like Ozempic and Zepbound no longer in shortage, access to medicine for millions who had ...

Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss t ...

The Business Research Company’s Huntington's Disease Global Market Report 2025 – Market Size, Trends, And Forecast 2025-2034 ...

The order gives drugmakers price targets in the next 30 days, and will take further action to lower prices if those companies do not make "significant progress" toward those goals ...